July 12, 2016 — Lantheus Holdings Inc., the parent company of Lantheus Medical Imaging Inc. (LMI), announced the first commercial shipment of Xenon Xe 133 gas (Xenon 133) using unprocessed radiochemical Xenon 133 supplied by the Institute for Radioelements (IRE) in Belgium.
Xenon 133 is an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and for imaging the lungs.
Earlier this month, Lantheus received approval from the U.S. Food and Drug Administration (FDA) for IRE to be a supplier of unprocessed radiochemical Xenon 133 for processing and finishing by Lantheus. IRE’s supply will supplement and eventually replace Lantheus’ current Xenon 133 supply when the National Research Universal (NRU) reactor in Canada no longer provides a regular supply of medical isotopes to the marketplace in October 2016.
For more information: www.lantheus.com
March 05, 2026 
